In his latest investment round, William Paiva poured money into an electrocardiogram administered via smartphone, a sickle-cell anemia treatment and a smoke alarm for the hearing-impaired. His portfolio is befitting of biotech’s birthplace in Cambridge, Massachusetts, or the tech hub of Silicon Valley. But Paiva manages the Oklahoma Life Science Fund in Oklahoma City, equidistant from Los Angeles and Washington.
